{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:21:14Z","timestamp":1790266874976,"version":"4.1.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1053\/j.semnuclmed.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T23:45:44Z","timestamp":1506037544000},"page":"4-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["PET\/CT for Staging; Past, Present, and Future"],"prefix":"10.1053","volume":"48","author":[{"given":"Tarec Christoffer","family":"El-Galaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Christian","family":"Gormsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0010","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: A 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/PPO.0b013e3181a27018","article-title":"Role of chemotherapy in Hodgkin's lymphoma","volume":"15","author":"Seam","year":"2009","journal-title":"Cancer J"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)77147-6","article-title":"The Nobel chronicles. 1979: Allan MacLeod Cormack (b 1924); and Sir Godfrey Newbold Hounsfield (b 1919)","volume":"354","author":"Raju","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1259\/bjr\/29444122","article-title":"CT scanning the early days","volume":"79","author":"Beckmann","year":"2006","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/bjc.1984.110","article-title":"A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: A report from the Manchester lymphoma group","volume":"49","author":"Anderson","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0040","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/1042819031000149430","article-title":"FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison","volume":"45","author":"Friedberg","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/cncr.10336","article-title":"Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma","volume":"94","author":"Kostakoglu","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0055","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"Tsukamoto","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"(18)F-FDG avidity in lymphoma readdressed: A study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hon.2181","article-title":"Role of 18F-FDG-PET\/CT in the management of marginal zone B cell lymphoma","volume":"33","author":"Carrillo-Cruz","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0070","first-page":"1","article-title":"18F-FDG PET\/CT and extragastric MALT lymphoma: Role of Ki-67 score and plasmacytic differentiation","author":"Albano","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","article-title":"High SUV uptake on FDG-PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma","volume":"20","author":"Ngeow","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0080","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.17219\/acem\/31804","article-title":"PET\/CT assessment of follicular lymphoma and high grade B cell lymphoma\u2014Good correlation with clinical and histological features at diagnosis","volume":"24","author":"Novelli","year":"2015","journal-title":"Adv Clin Exp Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0090","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0095","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1148\/radiology.203.3.9169707","article-title":"Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging","volume":"203","author":"Moog","year":"1997","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/028418699432969","article-title":"Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest","volume":"38","author":"Bangerter","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5","article-title":"2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial","volume":"91","author":"Buchmann","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0110","first-page":"1139","article-title":"Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma","volume":"42","author":"Schoder","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02988618","article-title":"Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma","volume":"16","author":"Sasaki","year":"2002","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1095-0397(01)00058-9","article-title":"2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma","volume":"4","author":"Delbeke","year":"2002","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1148\/radiology.206.2.9457202","article-title":"Extranodal malignant lymphoma: Detection with FDG PET versus CT","volume":"206","author":"Moog","year":"1998","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s002590050275","article-title":"Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography","volume":"25","author":"Stumpe","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0135","first-page":"343","article-title":"Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma","volume":"38","author":"Hoh","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00006231-199901000-00004","article-title":"Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma","volume":"20","author":"Jerusalem","year":"1999","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1259\/bjr.73.869.10884743","article-title":"The impact of FDG positron emission tomography imaging on the management of lymphomas","volume":"73","author":"Shah","year":"2000","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0150","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008486928190","article-title":"Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease","volume":"9","author":"Bangerter","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0155","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1008368330519","article-title":"2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution","volume":"11","author":"Partridge","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0160","first-page":"266","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-001-0390-y","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease","volume":"81","author":"Weihrauch","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0170","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdh426","article-title":"Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease","volume":"15","author":"Munker","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6601561","article-title":"Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma","volume":"90","author":"Naumann","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0180","first-page":"482","article-title":"Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0185","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-007-0356-9","article-title":"Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdj024","article-title":"Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET\/CT era?","volume":"17","author":"Raanani","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","article-title":"Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?","volume":"8","author":"Janikova","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","article-title":"Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma","volume":"71","author":"Wirth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0210","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0215","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0220","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4","article-title":"Whole body positron emission tomography in the treatment of Hodgkin disease","volume":"91","author":"Hueltenschmidt","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0225","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","article-title":"Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma","volume":"19","author":"Elstrom","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0230","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058482","article-title":"Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease","volume":"34","author":"Wiedmann","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0235","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/028418602320405014","article-title":"Positron emission tomography for the staging of Hodgkin's lymphoma\u2014Increasing the body of evidence in favor of the method","volume":"41","author":"Menzel","year":"2002","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/snuc.2003.127312","article-title":"Applications of positron emission tomography\/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements","volume":"33","author":"Cohade","year":"2003","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0245","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1157\/13112510","article-title":"[The value of positron emission tomography\/computed tomography (PET\/CT) in the staging of diffuse large B-cell lymphoma]","volume":"129","author":"Fuertes","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/gut.52.3.347","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma","volume":"52","author":"Hoffmann","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0255","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00277-003-0827-6","article-title":"18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum","volume":"83","author":"Hoffmann","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0260","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","article-title":"18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading","volume":"17","author":"Wohrer","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0265","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1011169332265","article-title":"Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)","volume":"12","author":"Jerusalem","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0270","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0275","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdi093","article-title":"FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases","volume":"16","author":"Beal","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0280","first-page":"115","article-title":"Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas","volume":"89","author":"Valencak","year":"2004","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0285","first-page":"37","article-title":"Diagnostic role of 18F-FDG pet in gastric MALT lymphoma","volume":"9","author":"Ambrosini","year":"2006","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0290","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/108497801753131372","article-title":"Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)","volume":"16","author":"Najjar","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0295","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000070290","article-title":"18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma","volume":"64","author":"Hoffmann","year":"2003","journal-title":"Oncology"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0300","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/10428190903440953","article-title":"SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma","volume":"51","author":"Watanabe","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0305","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00259-008-0771-8","article-title":"FDG avidity and PET\/CT patterns in primary gastric lymphoma","volume":"35","author":"Radan","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0310","first-page":"1796","article-title":"18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas","volume":"45","author":"Kumar","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0315","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ophtha.2006.04.029","article-title":"Whole-body positron emission tomography\/computed tomography imaging and staging of orbital lymphoma","volume":"113","author":"Roe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0320","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3816\/CLM.2007.n.008","article-title":"Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland","volume":"7","author":"Basu","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0325","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-0609.2007.00895.x","article-title":"Diagnostic accuracy of PET\/CT in patients with extranodal marginal zone MALT lymphoma","volume":"79","author":"Perry","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0330","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2967\/jnumed.108.053355","article-title":"Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer\/T-cell lymphomas of the head and neck","volume":"49","author":"Suh","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0335","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.mibio.2004.08.004","article-title":"Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography\/computed tomography hardware fusion for staging of patients with lymphoma","volume":"6","author":"Allen-Auerbach","year":"2004","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0340","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0345","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0350","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1053\/j.semnuclmed.2017.09.001_bib0355","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0360","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0365","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0370","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0375","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"Gutierrez-Garcia","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0380","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0385","doi-asserted-by":"crossref","first-page":"171","DOI":"10.6004\/jnccn.2015.0025","article-title":"CT-based versus FDG-PET\/CT-based NCCN international prognostic index risk stratification in DLBCL","volume":"13","author":"Adams","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0390","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ajh.24169","article-title":"Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0395","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3109\/10428194.2013.875169","article-title":"Impact of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: Fewer cases with stage I disease and more with skeletal involvement","volume":"55","author":"El-Galaly","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0400","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0405","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0410","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0415","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0420","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0425","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1053\/j.semnuclmed.2017.09.001_bib0430","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1053\/j.semnuclmed.2017.09.001_bib0435","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0440","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","article-title":"The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy","volume":"75","author":"El-Galaly","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0445","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0450","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","article-title":"Diffuse large B-cell lymphoma with involvement of the kidney: Outcome and risk of central nervous system relapse","volume":"96","author":"Villa","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0455","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0460","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0465","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0470","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0475","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1053\/j.semnuclmed.2017.09.001_bib0480","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0485","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0490","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00259-017-3647-y","article-title":"18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin's lymphoma: A quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement","volume":"44","author":"Hassan","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0495","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/annonc\/mdw137","article-title":"The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET\/CT: A Danish-Canadian study","volume":"27","author":"Alzahrani","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0500","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14071","article-title":"(18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma","volume":"174","author":"Ujjani","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0505","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-009-1377-5","article-title":"(18)F-FDG PET\/CT bone\/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging","volume":"37","author":"Moulin-Romsee","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0510","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.113.134486","article-title":"Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma","volume":"55","author":"Cerci","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0515","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3109\/10428194.2013.821201","article-title":"Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography-computed tomography era: A West of Scotland study","volume":"55","author":"Hamilton","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0520","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2967\/jnumed.116.184218","article-title":"Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin lymphoma: Results from an International Collaborative Study","volume":"58","author":"Zwarthoed","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0525","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/00313027909063538","article-title":"Bilateral trephine bone marrow biopsies in Hodgkin's and non-Hodgkin's lymphoma","volume":"11","author":"Menon","year":"1979","journal-title":"Pathology"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0530","first-page":"1293","article-title":"Morbidity associated with bone marrow aspiration and trephine biopsy\u2014A review of UK data for 2004","volume":"91","author":"Bain","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0535","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-011-1166-7","article-title":"Pain and anxiety associated with bone marrow aspiration and biopsy: A prospective study on 152 Italian patients with hematological malignancies","volume":"90","author":"Brunetti","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0540","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1399-6576.2008.01874.x","article-title":"Procedure-related pain among adult patients with hematologic malignancies","volume":"53","author":"Liden","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0545","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V91.9.3340","article-title":"Detection of lymphoma in bone marrow by whole-body positron emission tomography","volume":"91","author":"Carr","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0550","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.1998.16.2.603","article-title":"18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow","volume":"16","author":"Moog","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0555","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2004-01-0379","article-title":"Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma","volume":"105","author":"Vassilakopoulos","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0560","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.1995.13.2.403","article-title":"Bone marrow involvement in Hodgkin's disease: An analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group","volume":"13","author":"Munker","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0565","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3816\/CLM.2004.n.010","article-title":"A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma","volume":"5","author":"Levis","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0570","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3324\/haematol.2010.025072","article-title":"Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma","volume":"95","author":"Hines-Thomas","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0575","first-page":"134","article-title":"Is bone marrow trephine biopsy always mandatory in staging Hodgkin's disease?","volume":"90","author":"Cavalieri","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0580","first-page":"1733","article-title":"Hodgkin's disease of the bone marrow","volume":"31","author":"Rosenberg","year":"1971","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0585","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-82-3-365","article-title":"Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases","volume":"82","author":"Brunning","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0590","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1365-2141.2002.03842.x","article-title":"The value of bone marrow examination in the staging of Hodgkin's lymphoma: A review of 955 cases seen in a regional cancer centre","volume":"119","author":"Howell","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0595","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2010.32.4996","article-title":"[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma","volume":"29","author":"Purz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0600","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10428194.2011.616613","article-title":"Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the (18)F-fluoro-2-deoxyglucose positron emission tomography era","volume":"53","author":"Richardson","year":"2012","journal-title":"Leu Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0605","first-page":"469","article-title":"Bone marrow disease detection with FDG-PET\/CT and bone marrow biopsy during the staging of malignant lymphoma: Results from a large multicentre study","volume":"55","author":"Pelosi","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0610","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ajh.24044","article-title":"The role of bone marrow biopsy and FDG-PET\/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients","volume":"90","author":"Chen-Liang","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0615","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00259-014-2706-x","article-title":"Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET\/CT","volume":"41","author":"Weiler-Sagie","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0620","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0625","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1259\/bjr\/29583493","article-title":"Clinical utility of (1)(8)F FDG-PET\/CT in the detection of bone marrow disease in Hodgkin's lymphoma","volume":"85","author":"Muzahir","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0630","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12149-014-0920-z","article-title":"Bone marrow FDG-PET\/CT in Hodgkin lymphoma revisited: Do imaging and pathology match?","volume":"29","author":"Adams","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0635","series-title":"Role of bone marrow biopsy in Hodgkin lymphoma staging in the PET\/CT era","author":"Puccini","year":"2014"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0640","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0645","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12483","article-title":"Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: Incidence and relevance","volume":"95","author":"Adams","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0650","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","article-title":"Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: A reflection of disease infiltration or just inflammation?","volume":"36","author":"Salaun","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0655","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0660","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood-2007-01-070300","article-title":"Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index","volume":"110","author":"Chung","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0665","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.953","article-title":"Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome","volume":"29","author":"Chigrinova","year":"2011","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0670","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jclinpath-2012-201158","article-title":"Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP","volume":"66","author":"Shim","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0675","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0680","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00277-011-1353-6","article-title":"Role of FDG-PET\/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma","volume":"91","author":"Hong","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0685","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ajh.23730","article-title":"Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma","volume":"89","author":"Adams","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0690","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00259-006-0238-8","article-title":"Bone involvement in patients with lymphoma: The role of FDG-PET\/CT","volume":"34","author":"Schaefer","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0695","first-page":"958","article-title":"18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis","volume":"46","author":"Pakos","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0700","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","article-title":"In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy","volume":"54","author":"Berthet","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0705","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00259-008-1021-9","article-title":"Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate","volume":"36","author":"Paone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0710","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/0284185114554824","article-title":"Direct comparison of visual and quantitative bone marrow FDG-PET\/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: Does bone marrow FDG-PET\/CT live up to its promise?","volume":"56","author":"Adams","year":"2015","journal-title":"Acta Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0715","doi-asserted-by":"crossref","first-page":"e2910","DOI":"10.1097\/MD.0000000000002910","article-title":"The value of PET\/CT in detecting bone marrow involvement in patients with follicular lymphoma","volume":"95","author":"Perry","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0720","first-page":"1","article-title":"Accuracy of 18-F FDG PET\/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma\u2014Tissue remains the issue","author":"Pham","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0725","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdm265","article-title":"FDG-PET in T-cell and NK-cell neoplasms","volume":"18","author":"Kako","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0730","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: A review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0735","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0740","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MD.0000000000000050","article-title":"Initial staging of Hodgkin's disease: Role of contrast-enhanced 18F FDG PET\/CT","volume":"93","author":"Chiaravalloti","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0745","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3109\/10428194.2014.900761","article-title":"Clinical impact of contrast-enhanced computed tomography combined with low-dose (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography on routine lymphoma patient management","volume":"55","author":"Chalaye","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0750","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1148\/radiol.2323030985","article-title":"Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging\u2014Do we need contrast-enhanced CT?","volume":"232","author":"Schaefer","year":"2004","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0755","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2967\/jnumed.107.043109","article-title":"Limitations of CT during PET\/CT","volume":"48","author":"Gollub","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0760","first-page":"567","article-title":"Diagnostic value of CT, PET and combined PET\/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma","volume":"55","author":"Pinilla","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0765","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/s00259-009-1306-7","article-title":"Methodological considerations in quantification of oncological FDG PET studies","volume":"37","author":"Vriens","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0770","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00259-005-1784-1","article-title":"PET\/CT with intravenous contrast can be used for PET attenuation correction in cancer patients","volume":"32","author":"Berthelsen","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0775","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejrad.2015.12.006","article-title":"Comparison between whole-body MRI with diffusion-weighted imaging and PET\/CT in staging newly diagnosed FDG-avid lymphomas","volume":"85","author":"Albano","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0780","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1007\/s00259-017-3726-0","article-title":"Imaging children suffering from lymphoma: An evaluation of different 18F-FDG PET\/MRI protocols compared to whole-body DW-MRI","volume":"44","author":"Kirchner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0785","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.acra.2014.05.019","article-title":"FDG PET\/MR for the assessment of lymph node involvement in lymphoma: Initial results and role of diffusion-weighted MR","volume":"21","author":"Platzek","year":"2014","journal-title":"Acad Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0790","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/RLI.0000000000000218","article-title":"18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance in lymphoma: Comparison with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging","volume":"51","author":"Giraudo","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0795","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000001344","article-title":"Comparison of PET\/MRI with PET\/CT in the evaluation of disease status in lymphoma","volume":"42","author":"Afaq","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0800","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/3337","article-title":"Imaging proliferation in vivo with [F-18]FLT and positron emission tomography","volume":"4","author":"Shields","year":"1998","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0805","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/1084978041979652","article-title":"[18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: Whole-body biodistribution and imaging of lymphoma manifestations\u2014A pilot study","volume":"19","author":"Buchmann","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2017.09.001_bib0810","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1158\/0008-5472.CAN-06-1955","article-title":"Molecular imaging of proliferation in malignant lymphoma","volume":"66","author":"Buck","year":"2006","journal-title":"Cancer Res"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299817300788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T06:51:44Z","timestamp":1693032704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299817300788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":161,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0001299817300788"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT for Staging; Past, Present, and Future","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}